Gossamer Bio Enters Into Securities Purchase Agreement for Up to $250 Million Private Placement

Filing content

The company entered into a private placement agreement for up to $250 million, contingent on FDA milestones, involving the issuance of pre-funded warrants and convertible preferred stock subject to stockholder approval.